15.05
-0.37(-2.40%)
Currency In USD
| Previous Close | 15.42 |
| Open | 15.33 |
| Day High | 15.62 |
| Day Low | 14.16 |
| 52-Week High | 19.41 |
| 52-Week Low | 3.39 |
| Volume | 615,501 |
| Average Volume | 349,337 |
| Market Cap | 197.94M |
| PE | 2.3 |
| EPS | 6.54 |
| Moving Average 50 Days | 13.61 |
| Moving Average 200 Days | 8.15 |
| Change | -0.37 |
If you invested $1000 in Avalo Therapeutics, Inc. (AVTX) 10 years ago, it would be worth $0.9 as of November 09, 2025 at a share price of $15.05. Whereas If you bought $1000 worth of Avalo Therapeutics, Inc. (AVTX) shares 5 years ago, it would be worth $2.54 as of November 09, 2025 at a share price of $15.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the C
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expans
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
GlobeNewswire Inc.
Sep 22, 2025 11:00 AM GMT
WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appoi